Literature DB >> 8825191

Synthesis of putative metabolites and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4-methylphenylsulfonyl) urea], in diabetic patients.

A R Taylor1, R D Brownsill, H Grandon, F Lefoulon, A Petit, W Luijten, P G Kopelman, B Walther.   

Abstract

Synthesis of postulated hydroxylated metabolites of gliclazide is described together with their detailed structural analysis using 1H-NMR, two-dimensional 1H-NMR, and MS to characterize the products. Metabolism of gliclazide has been investigated in the urine of nine patients of different ethnic origins receiving gliclazide therapy for the treatment of diabetes. Urine extracts were analyzed by GC/MS to quantify and identify the metabolites excreted in urine and the metabolites compared with the synthesized products. Metabolic profiles in all diabetic patients were very similar and comparable with those reported for healthy human volunteers. In addition to the expected metabolites arising from oxidation of the 4-methylphenyl ring, four isomeric hydroxylated products of the azabicyclooctyl ring were identified and the structure of a fifth isomer postulated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825191

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Authors:  Yifan Zhang; Dayong Si; Xiaoyan Chen; Nan Lin; Yingjie Guo; Hui Zhou; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

2.  Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.

Authors:  H Xu; K M Williams; W S Liauw; M Murray; R O Day; A J McLachlan
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

3.  Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Authors:  David J Elliot; Benjamin C Lewis; Elizabeth M J Gillam; Donald J Birkett; Annette S Gross; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.